Gilead Sciences today announced three-year efficacy and safety results from two pivotal Phase 3 studies evaluating the once-daily single tablet regimen Stribild among treatment-naive patients with HIV-1 infection.
http://www.benzinga.com/news/13/10/3994933/gileads-stribild-demonstrates-durable-viral-suppression-in-two-phase-3-studies
http://www.benzinga.com/news/13/10/3994933/gileads-stribild-demonstrates-durable-viral-suppression-in-two-phase-3-studies
No comments:
Post a Comment